Zacks Investment Research Lowers OptiNose (NASDAQ:OPTN) to Sell

Zacks Investment Research downgraded shares of OptiNose (NASDAQ:OPTN – Get Rating) from a buy rating to a sell rating in a research note published on Saturday morning, Zacks.com reports. According to Zacks, “OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and […]

Related Keywords

Pennsylvania ,United States ,Helena Kyttari Djupesland ,Gisle Djupesland ,Virtu Financial ,Zacks Investment Research ,De Shaw Co ,Buckingham Strategic Wealth ,Optinose Inc ,Cantor Fitzgerald ,Boothbay Fund Management ,Citadel Advisors ,Get Rating ,Strategic Wealth ,Fund Management ,Per Gisle Djupesland ,Optinose ,Nasdaq Optn ,Optn ,Medical ,Downgrade ,